Morgan Stanley’s Indaptus Therapeutics INDP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $26.8K | Buy |
8,936
+6,239
| +231% | +$15.7K | ﹤0.01% | 6717 |
|
|
2026
Q1 | $4.91K | Buy |
+2,697
| New | +$5.78K | ﹤0.01% | 7141 |
|
|
2025
Q2 | – | Sell |
-32
| Closed | -$486 | – | 8189 |
|
|
2025
Q1 | $486 | Hold |
32
| – | – | ﹤0.01% | 7374 |
|
|
2024
Q4 | $744 | Hold |
32
| – | – | ﹤0.01% | 7306 |
|
|
2024
Q3 | $1.1K | Hold |
32
| – | – | ﹤0.01% | 7212 |
|
|
2024
Q2 | $1.87K | Hold |
32
| – | – | ﹤0.01% | 7077 |
|
|
2024
Q1 | $1.98K | Hold |
32
| – | – | ﹤0.01% | 7074 |
|
|
2023
Q4 | $1.55K | Sell |
32
-5
| -14% | -$314 | ﹤0.01% | 7078 |
|
|
2023
Q3 | $2.83K | Buy |
37
+7
| +23% | +$473 | ﹤0.01% | 7050 |
|
|
2023
Q2 | $1.58K | Hold |
30
| – | – | ﹤0.01% | 7227 |
|
|
2023
Q1 | $1.53K | Buy |
30
+11
| +58% | +$519 | ﹤0.01% | 7286 |
|
|
2022
Q4 | $767 | Hold |
19
| – | – | ﹤0.01% | 7508 |
|
|
2022
Q3 | $1K | Hold |
19
| – | – | ﹤0.01% | 7567 |
|
|
2022
Q2 | $1K | Sell |
19
-1
| -5% | -$78 | ﹤0.01% | 7684 |
|
|
2022
Q1 | $2K | Hold |
20
| – | – | ﹤0.01% | 7742 |
|
|
2021
Q4 | $3K | Hold |
20
| – | – | ﹤0.01% | 7741 |
|
|
2021
Q3 | $4K | Sell |
20
-291
| -94% | -$84K | ﹤0.01% | 7541 |
|
|
2021
Q2 | $121K | Buy |
311
+301
| +3,010% | +$133K | ﹤0.01% | 6267 |
|
|
2021
Q1 | $5K | Sell |
10
-101
| -91% | -$52.9K | ﹤0.01% | 7104 |
|
|
2020
Q4 | $43K | Buy |
111
+104
| +1,486% | +$45.4K | ﹤0.01% | 6202 |
|
|
2020
Q3 | $4K | Buy |
7
+2
| +40% | +$1.47K | ﹤0.01% | 6472 |
|
|
2020
Q2 | $3K | Sell |
5
-15
| -75% | -$9.27K | ﹤0.01% | 6391 |
|
|
2020
Q1 | $9K | Buy |
20
+17
| +567% | +$12.8K | ﹤0.01% | 6041 |
|
|
2019
Q4 | $4K | Sell |
3
-4
| -57% | -$5.52K | ﹤0.01% | 6427 |
|
|
2019
Q3 | $12K | Sell |
7
-30
| -81% | -$89.3K | ﹤0.01% | 6148 |
|
|
2019
Q2 | $356K | Buy |
37
+11
| +42% | +$139K | ﹤0.01% | 4771 |
|
|
2019
Q1 | $434K | Buy |
26
+12
| +86% | +$210K | ﹤0.01% | 4624 |
|
|
2018
Q4 | $239K | Sell |
14
-3
| -18% | -$40.9K | ﹤0.01% | 5210 |
|
|
2018
Q3 | $210K | Buy |
17
+1
| +6% | +$9.5K | ﹤0.01% | 5436 |
|
|
2018
Q2 | $158K | Buy |
16
+2
| +14% | +$22.2K | ﹤0.01% | 5617 |
|
|
2018
Q1 | $189K | Buy |
+14
| New | +$198K | ﹤0.01% | 5493 |
|
|
2017
Q4 | – | Hold |
0
| – | -$4K | – | 6599 |
|
|
2017
Q3 | – | Hold |
0
| – | – | – | 6321 |
|
|
2016
Q2 | – | Hold |
0
| – | – | – | 6570 |
|
|
2016
Q1 | – | Hold |
0
| – | – | – | 6639 |
|
|
2015
Q4 | – | Hold |
0
| – | – | – | 6721 |
|
Other funds holding INDP
HF
SS
Morgan Stanley's INDP Position: Q2 2026 in Review
Morgan Stanley increased its Indaptus Therapeutics (INDP) stake by 231% in Q2 2026, buying an estimated $15.7K and bringing the position to 8,936 shares worth $26.8K. The position accounts for ﹤0.01% of the portfolio, ranked #6717.
Morgan Stanley first reported a position in INDP in Q1 2018 and has held it in 31 quarters since. The position peaked at $434K in Q1 2019. 9 funds tracked by Wall St. Rank hold INDP as of Q2 2026.
- Morgan Stanley held 8,936 shares of Indaptus Therapeutics worth $26.8K as of Q2 2026.
- Morgan Stanley bought 6,239 Indaptus Therapeutics shares in Q2 2026, an estimated $15.7K.
- Indaptus Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #6717 holding.
- Morgan Stanley first reported a position in Indaptus Therapeutics in Q1 2018 and has held it in 31 quarters since.
- Morgan Stanley's Indaptus Therapeutics position peaked at $434K in Q1 2019.
- 9 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q2 2026.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.